[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1247613A1 - 炔基吡啶類脯氨酰羥化酶抑制劑、其製備方法和醫藥用途 - Google Patents

炔基吡啶類脯氨酰羥化酶抑制劑、其製備方法和醫藥用途

Info

Publication number
HK1247613A1
HK1247613A1 HK18107005.8A HK18107005A HK1247613A1 HK 1247613 A1 HK1247613 A1 HK 1247613A1 HK 18107005 A HK18107005 A HK 18107005A HK 1247613 A1 HK1247613 A1 HK 1247613A1
Authority
HK
Hong Kong
Prior art keywords
preparation
medical use
prolyl hydroxylase
hydroxylase inhibitor
alkynyl pyridine
Prior art date
Application number
HK18107005.8A
Other languages
English (en)
Inventor
尤启冬
張曉進
雷永華
胡天寒
吳杏森
孫昊鵬
郭小可
徐曉莉
Original Assignee
江蘇恒瑞醫藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江蘇恒瑞醫藥股份有限公司 filed Critical 江蘇恒瑞醫藥股份有限公司
Publication of HK1247613A1 publication Critical patent/HK1247613A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK18107005.8A 2015-10-09 2018-05-29 炔基吡啶類脯氨酰羥化酶抑制劑、其製備方法和醫藥用途 HK1247613A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510648342.9A CN105130888A (zh) 2015-10-09 2015-10-09 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途
PCT/CN2015/095728 WO2017059623A1 (zh) 2015-10-09 2015-11-27 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途

Publications (1)

Publication Number Publication Date
HK1247613A1 true HK1247613A1 (zh) 2018-09-28

Family

ID=54716523

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18107005.8A HK1247613A1 (zh) 2015-10-09 2018-05-29 炔基吡啶類脯氨酰羥化酶抑制劑、其製備方法和醫藥用途

Country Status (21)

Country Link
US (2) US10889546B2 (zh)
EP (1) EP3360862B1 (zh)
JP (1) JP6635562B2 (zh)
KR (1) KR20180063229A (zh)
CN (2) CN105130888A (zh)
AU (1) AU2015411258B2 (zh)
BR (1) BR112018005969A2 (zh)
CA (1) CA3000040A1 (zh)
DK (1) DK3360862T3 (zh)
ES (1) ES2794002T3 (zh)
HK (1) HK1247613A1 (zh)
HR (1) HRP20200907T1 (zh)
HU (1) HUE049409T2 (zh)
LT (1) LT3360862T (zh)
MX (1) MX2018003832A (zh)
PL (1) PL3360862T3 (zh)
PT (1) PT3360862T (zh)
RU (1) RU2692494C1 (zh)
SI (1) SI3360862T1 (zh)
UA (1) UA120407C2 (zh)
WO (1) WO2017059623A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105130888A (zh) 2015-10-09 2015-12-09 中国药科大学 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途
CN107417605A (zh) * 2017-08-02 2017-12-01 江苏艾立康药业股份有限公司 作用于脯氨酰羟化酶的吡啶衍生化合物
TW201917117A (zh) * 2017-10-25 2019-05-01 大陸商江蘇恆瑞醫藥股份有限公司 一種炔基吡啶類脯胺醯羥化酶抑制劑的晶型及其製備方法
CN110240562B (zh) * 2018-03-08 2022-04-12 江苏恒瑞医药股份有限公司 一种脯氨酰羟化酶抑制剂的可药用盐、晶型及其制备方法
US20210206720A1 (en) 2018-05-24 2021-07-08 Suzhou Suncadia Biopharmaceuticals Co., Ltd. Method for preparing alkynyl pyridine prolyl hydroxylase inhibitor
CN109593084B (zh) * 2019-01-23 2021-09-28 中国药科大学 脯氨酰羟化酶小分子光敏前药及其制备方法与应用
WO2020177681A1 (zh) * 2019-03-04 2020-09-10 江苏恒瑞医药股份有限公司 一种脯氨酰羟化酶抑制剂的药物组合物及其制备方法
CN112741834A (zh) * 2021-02-07 2021-05-04 复旦大学附属中山医院 HIF-1α降解抑制剂在制备酮体水平升高的冠心病药物中的应用
CN116120340B (zh) * 2021-11-15 2023-10-31 艾立康药业股份有限公司 一种吡啶并噁嗪类化合物及其制备方法、组合物和用途
CN116514710B (zh) * 2022-01-21 2024-07-05 中国药科大学 环取代炔基吡啶甲酰甘氨酸衍生物、制备方法、药物组合物和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4410480A1 (de) * 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP3026044B8 (en) * 2006-06-26 2018-12-19 Akebia Therapeutics, Inc. Prolyl hydroxylase inhibitors and methods of use
ES2393326T3 (es) * 2006-12-18 2012-12-20 Amgen, Inc Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos
TW200845991A (en) * 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
WO2011132633A1 (ja) * 2010-04-19 2011-10-27 第一三共株式会社 置換５－ヒドロキシピリミジン－４－カルボキサミド化合物
US9738604B2 (en) * 2010-09-03 2017-08-22 Duke University Ethynylbenzene derivatives
KR102029951B1 (ko) 2011-07-22 2019-11-08 베이징 베타 파머수티컬 컴퍼니 리미티드 프로릴 히드록실라제 억제제로서 화합물의 다형체형, 및 이의 용도
CN105130888A (zh) * 2015-10-09 2015-12-09 中国药科大学 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途

Also Published As

Publication number Publication date
US20200407319A1 (en) 2020-12-31
CA3000040A1 (en) 2017-04-13
LT3360862T (lt) 2020-07-10
UA120407C2 (uk) 2019-11-25
DK3360862T3 (da) 2020-06-02
ES2794002T3 (es) 2020-11-17
HUE049409T2 (hu) 2020-10-28
CN107848976B (zh) 2020-11-17
BR112018005969A2 (zh) 2018-10-16
US10889546B2 (en) 2021-01-12
AU2015411258A1 (en) 2018-05-10
CN105130888A (zh) 2015-12-09
EP3360862A1 (en) 2018-08-15
EP3360862B1 (en) 2020-04-22
PT3360862T (pt) 2020-05-27
MX2018003832A (es) 2018-06-18
JP2018529690A (ja) 2018-10-11
AU2015411258B2 (en) 2020-09-17
RU2692494C1 (ru) 2019-06-25
WO2017059623A1 (zh) 2017-04-13
CN107848976A (zh) 2018-03-27
EP3360862A4 (en) 2018-08-15
HRP20200907T1 (hr) 2020-09-04
SI3360862T1 (sl) 2020-08-31
PL3360862T3 (pl) 2020-09-21
KR20180063229A (ko) 2018-06-11
JP6635562B2 (ja) 2020-01-29
US20180305317A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
HK1247613A1 (zh) 炔基吡啶類脯氨酰羥化酶抑制劑、其製備方法和醫藥用途
PT3546457T (pt) Derivado de pirazolo-heteroarílico, método de preparação e a utilização médica do mesmo
HK1251551A1 (zh) 氮雜環丁烷衍生物、其製備方法及用途
IL259711A (en) Methods for the preparation of protein kinase inhibitors and their medical use
PL3181560T3 (pl) Pochodna pirydynoamidopirymidyny, sposób jej otrzymywania i zastosowanie
HK1244808A1 (zh) 苯並哌啶類衍生物、其製備方法及其在醫藥上的應用
EP3363348A4 (en) PHYSIOLOGICAL STATE DETERMINATION DEVICE AND PHYSIOLOGICAL STATE DETERMINING METHOD
ZA202002517B (en) Compounds and methods for reducing snca expression
EP3356976A4 (en) METHOD FOR ASSESSING THE NORMALITY OF AN IMMUNORE TERRE AND THE USE THEREOF
HK1243997B (zh) Kv1．3抑制劑及其醫學應用
GB201907083D0 (en) 99mtc-labelled isonitrile-containing glucose derivative and preparation method and use
SG11201800235RA (en) Patient status determination device, patient status determination method and program
EP3381919A4 (en) Substituted triazolopiperazine parp inhibitor, preparation method therefor, and use thereof
EP3299488A4 (en) Carburization device and carburization method
EP3381921A4 (en) GINKGOLIDE B DERIVATIVE AND METHOD OF PREPARING THEREOF AND USE THEREOF
IL258690A (en) Pyridone derivatives and their use as kinase inhibitors
EP3253734A4 (en) Glucosylceramide synthase inhibitors and therapeutic methods using the same
HK1243998A1 (zh) Kv1．3抑制劑及其醫學應用
EP3313488A4 (en) DEVICE AND METHOD FOR OXYGEN BIOFEEDBACK
EP3181177B8 (fr) Nécessaire de traitement, dispositif de mesure et utilisation associés